A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: A dose- and schedule-finding study

Clinical Cancer Research

Volumn 16, Issue 20, 2010, Pages 5079-5086

  Lonial, Sagar ^a   Kaufman, Jonathan ^a   Tighiouart, Mourad ^a   Nooka, Ajay ^a   Langston, Amelia A ^a   Heffner, Leonard T ^a   Torre, Claire ^a   McMillan, Stephanie ^a   Renfroe, Heather ^a   Harvey, R Donald ^a   Lechowicz, Mary J ^a   Khoury, H Jean ^a   Flowers, Christopher R ^a   Waller, Edmund K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MELPHALAN;

ADULT; AGED; ARTICLE; BLISTER; BONE PAIN; CELL DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COGNITIVE DEFECT; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; HYPERNATREMIA; INCONTINENCE; LIVER TOXICITY; LUNG EMBOLISM; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SEPSIS; SINUS BRADYCARDIA; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; URINE RETENTION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; TRANSPLANTATION CONDITIONING;

EID: 77958065790     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1662     Document Type: Article

References (37)

1. Harousseau JL, Attal M. The role of autologous hematopoietic stem cell transplantation in multiple myeloma. Semin Hematol 1997;34:61-6.
2. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. Stem Cells 1995;13 Suppl 2:132-9.
3. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
4. Harousseau JL, Avet-Loiseau H, Attal M, et al. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. J Clin Oncol 2009;27:5720-6.
5. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
6. Giralt S, Vesole DH, Somlo G, et al. Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009;101:964, author reply 966-7.
7. Harousseau JL, Moreau P. Evolving role of stem cell transplantation in multiple myeloma. Clin Lymphoma Myeloma 2005;6:89-95.
8. Lahuerta JJ, Grande C, Martinez-Lopez J, et al. Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Espanol de Sindromes Linfoproliferativos/Trasplante Autologo de Medula Osea phase II trial. Br J Haematol 2003;120:296-303.
9. Brinker BT, Waller EK, Leong T, et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 2006;106:2171-80.
10. Desikan KR, Tricot G, Dhodapkar M, et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone. Bone Marrow Transplant 2000;25:483-7.
11. Shimoni A, Smith TL, Aleman A, et al. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. Bone Marrow Transplant 2001;27:821-8.
12. Anagnostopoulos A, Aleman A, Ayers G, et al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004;100:2607-12.
13. Christoforidou AV, Saliba RM, Williams P, et al. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 2007;13:543-9.
14. Giralt S, Bensinger W, Goodman M, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003;102:2684-91.
15. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-5.
16. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
17. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518-25.
18. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
19. Hideshima T, Chauhan D, Ishitsuka K, et al. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors. Oncogene 2005;24:3121-9.
20. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
21. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
22. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
23. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901.
24. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44.
25. Lonial S, Jones TW, Devine S, et al. High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma. Leuk Lymphoma 2000;36:497-502.
26. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 1998;17:1103-20. (Pubitemid 28221028)
27. Babb JS, Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Stat Med 2001;20:2079-90. (Pubitemid 32684630)
28. Tighiouart M, Rogatko A, Babb JS. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control. Stat Med 2005;24:2183-96.
29. Zacks S, Rogatko A, Babb J. Optimal Bayesian-feasibile dose escalation for cancer phase I trials. Stat Prob Ltrs 1998;38:215-20. (Pubitemid 128181982)
30. Kumar S, Dingli D, Dispenzieri A, et al. Impact of additional cytoreduction following autologous SCT in multiple myeloma. Bone Marrow Transplant 2008;42:259-64.
31. Roussel M, Moreau P, Huynh A, et al. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Blood 2010;115:32-7.
32. Pineda-Roman M, Fox MH, Hollmig KA, et al. Retrospective analysis of fractionated high-dosemelphalan (F-MEL) and bortezomib-thalidomide-dexamethasone (VTD) with autotransplant (AT) support for advanced and refractory multiple myeloma (AR-MM). ASH Annu Meet Abst 2006;108:3102.
33. Qazilbash MH, Saliba RM, Pelosini M, et al. A randomized phase II trial of high-dose melphalan, ascorbic acid and arsenic trioxide with or without bortezomib in multiple myeloma. ASH Annu Meet Abstr 2008;112:3320.
34. Zou W, Yue P, Lin N, et al. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 2006;12:273-80.
35. Harvey RD, Nettles J, Wang B, Sun SY, Lonial S. Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'. Leukemia 2009;23:1939-40.
36. Perrone G, Hideshima T, Ikeda H, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 2009;23:1679-86.
37. Popat R, Oakervee H, Williams C, et al. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol 2009;144:887-94.